Drugs Made In America Acquisition DMAAR Balance Sheet (2024-2026)

NASDAQ DMAAR
$0.13 +0.01 (+8.33%)
At close: Sep 17, 2026 · 4:00 PM EDT
Reported Financials

Drugs Made In America Acquisition Quarterly Balance Sheet

Periods 6 quarters
Latest Jun 2026

Drugs Made In America Acquisition reported total assets of $146.90M and total liabilities of $9.14M for the quarter ended Jun 2026, down 36.9% year over year. This balance sheet covers 6 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Balance Sheet Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Assets
Current Assets
Cash & EquivalentsCash & Equiv. 0.00M923.00822.00717.000.01M0.02M
Prepaid Assets 0.00M0.07M0.05M0.03M0.01M0.05M
Current Assets 0.00M0.07M0.05M0.03M0.01M0.07M
Non-Current Assets
Long-Term Investments 232.74M235.16M237.60M239.91M146.83M
Other Non-Current Assets 0.55M
Non-Current Assets 0.55M232.74M235.16M237.60M239.91M146.83M
Assets 0.55M232.81M235.21M237.63M239.92M146.90M
Liabilities
Current Liabilities
Accounts Payables 0.08M0.00M0.08M0.22M0.25M
Notes Payables 0.66M0.06M0.35M
Payables 0.74M0.06M0.00M0.08M0.22M0.60M
Accumulated Expenses 0.08M0.13M0.15M0.30M0.01M
Total Current Liabilities 0.80M0.35M0.30M0.46M0.38M2.94M
Non-Current Liabilities
Non-Current Debt 0.66M0.06M
Non-Current Deffered Revenue 6.90M6.90M6.90M6.90M6.19M
Preferred Stock Liabilities 232.74M235.16M237.60M239.91M145.17M
Total Non-Current Liabilities 6.90M6.19M
Total Liabilities 0.80M7.25M7.20M7.36M7.28M9.14M
Shareholder's Equity
Total Debt 1.32M0.12M0.35M
Common Equity -0.24M-7.18M-7.15M-7.33M-7.26M-7.41M
Liabilities and Shareholders Equity 0.55M232.81M235.21M237.63M239.92M146.90M
Retained Earnings -0.28M-6.33M-6.46M-6.72M-7.27M-7.41M
Treasury Shares 23.00M23.00M23.00M23.00M13.56M